Integra Lifesciences Corporation and Stryker Is Dominating the Market for Global Nerve Repair Biomaterials Market In 2016

Global Nerve Repair Biomaterials Market is expected to reach USD 775.59 million by 2024 from USD  326.71 million in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024. The new market report contains data for historic year 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Access Full Report: Repair Biomaterials Market Geographical OverviewThe nerve repair biomaterials market comprises of a few large and small players. The market is expected to witness competition in terms of new product launches, the introduction of new treatment options to meet changing customer requirements, and evolving industry standards in the forecast period 2017 to 2024. Integra LifeSciences Corporation dominated the nerve repair biomaterials market accounting for a highest market share in 2016, followed by Stryker and AxoGen, Inc. Other players in this market include Checkpoint Surgical, Inc., Collagen Matrix, Inc., Polyganics, B.V., and Synovis Micro Companies Alliance, Inc.26.3% of the global nerve repair biomaterials market in 2016.


Founded in 1989 and headquartered in Plainsboro, New Jersey (U.S). Integra Lifesciences Corporation is engaged in the manufacturing and sales of medical instruments, devices, and equipment. It operates through the specialty surgical solutions, and orthopedics and tissue technologies segments. The specialty surgical solutions segment offers specialty surgical instrumentation for a broad range of specialties, such as products and solutions for dural repair, precision tools and instruments, tissue ablation, and neuro critical care.


Founded in 1941 and headquartered in Michigan, U.S., Stryker Corporation specializes in reconstructive, medical and surgical, and neurotechnology& spine products. The company has three business segments—orthopedic implants, medsurg, and neurotechnology and spine. The Medsurg segment focuses on surgical equipment, minimally invasive surgical solutions, sports medicine, and patient handling, and provides medical products for a variety of specialties.

Recent Developments:

In April 2016, Stryker Corporation announced the completion of its previously announced acquisition of Synergetics USA, Inc.'s Neuro Portfolio.


Incorporated in 1977 and headquartered in Alachua, Florida. AxoGen, Inc., is a regenerative medicine company, which is focused on science, development, and commercialization of technologies for peripheral nerve solutions.Thecompany’s distribution channel extends from U.S., Canada, and many other countries either through direct distribution or through distributors. Some of the international partners through which AxoGen is operating outside North America are Crosstec GmbH, Anexxa Medical Technologies Inc., Fortis Technologies Ltd., MD For Life, Semenza Medical Solutions, Neutromedics and Hospital Innovations.

Recent Developments:

  • In November 2016, AxoGen, Inc., announced the commercial release and first clinical implant of Avive Soft Tissue Membrane which is a minimally processed human umbilical cord membrane delivering the benefits of amnion to reduce inflammation and scar tissue formation.
  • In March 2016, AxoGen, Inc., announced the commercial release and first sale of AcroVal Neurosensory & Motor Testing System (NSMTS) which is a nerve function evaluation solution for surgeons and other allied health professionals for electronically measuring, mapping, and monitoring patients with peripheral nerve injuries and conditions.